Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer-Reference-Cited by-同舟云学术

Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer

Published:2017-03-14 Issue:4 Volume:27 Page:461-482
ISSN:1001-0602
Container-title:Cell Research
language:en
Short-container-title:Cell Res

Author:

Su Shicheng,Liao Jianyou,Liu Jiang,Huang Di,He Chonghua,Chen Fei,Yang LinBing,Wu Wei,Chen Jianing,Lin Ling,Zeng Yunjie,Ouyang Nengtai,Cui Xiuying,Yao Herui,Su Fengxi,Huang Jian-dong,Lieberman Judy,Liu Qiang,Song Erwei

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/cr201734.pdf

Reference55 articles.

1. Zitvogel L, Tanchot C, Granier C, Tartour E . Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology 2013; 2:e25444.

2. Nishikawa H, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1–7.

3. Beyer M, Schultze JL . Regulatory T cells in cancer. Blood 2006; 108:804–811.

4. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942–949.

5. Telang S, Rasku MA, Clem AL, et al. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer 2011; 11:515.

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefit delayed immunosenescence by regulating CD4⁺T cells: A promising therapeutic target for aging‐related diseases;Aging Cell;2024-08-18

2. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies;Experimental Hematology & Oncology;2024-08-06

3. Spatial heterogeneity and prognostic significance of TAMs and TILs infiltrates in different staging esophageal squamous carcinoma;Digestive and Liver Disease;2024-08

4. Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer;Molecular Therapy;2024-07

5. Breast Cancer Immune Landscape: Interplay Between Systemic and Local Immunity;Advanced Biology;2024-05-10